More evidence needed to support BRAHMS copeptin test, says NICE in draft guidance
This article was originally published in Clinica
A copeptin assay developed by Germany’s BRAHMS to help rule out myocardial infarction (MI) “shows potential” for being used routinely by the UK’s NHS. However, more evidence on its impact in clinical practice is required, concluded the National Institute for Health and Clinical Excellence (NICE) in draft guidance issued today for consultation.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.